SOX9 is a key component of RUNX2-regulated transcriptional circuitry in osteosarcoma
Osteosarcoma (OS) is the most common bone cancer in children and adolescents. Although the 5-year survival rate of most OS is more than 70%, it drops to 25% for those with recurrent or metastasized tumors. Furthermore, the standard care of OS has not changed in the past three or more decades, and there is no FDA-approved targeted therapy and immunotherapy for OS. Therefore, there is a great need to develop new therapeutic targets to reduce side effects and improve the prognosis for OS patients. The lack of targetable genetic alterations in OS suggests that transcriptional and epigenetic events are involved in the etiology ...
Source: Videocast - All Events - September 5, 2023 Category: General Medicine Tags: Upcoming Events Source Type: video
Oncogene Addiction
NCI Center for Cancer Research Eminent Lecture
Dr. Felsher obtained a B.A. in Chemistry at the University of Chicago, a M.D. Ph.D. from the University of California, Los Angeles School of Medicine. He performed his graduate work in Molecular Biology/Immunology under Dr. Jonathan Braun. He trained in Internal Medicine at the Hospital of the University of Pennsylvania and Oncology at the University of California, San Francisco and his post-doctoral research under Dr. J. Michael Bishop. Dr. Felsher has been faculty at Stanford University for 16 years and performing both basic and translational cancer research and is the foun...
Source: Videocast - All Events - May 18, 2016 Category: Journals (General) Tags: Upcoming Events Source Type: video
